{"id":"5eb2e10fe0b8","type":"article","url":"https://hartvaat.nl/2021/06/01/metabole-effecten-van-empagliflozine-bij-hf-empire-hf-metabolic-gerandomiseerde-/","title":"Metabole effecten van empagliflozine bij HF: Empire HF Metabolic gerandomiseerde trial","title_en":"Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic).","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["dapa-hf","emperor-trials"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.120.053463","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.120.053463","authors":["Jesper Jensen","Massar Omar","Caroline Kistorp","Christian Tuxen","Ida Gustafsson","Lars Køber","Finn Gustafsson","Jens Faber","Julie L Forman","Jacob E Møller","Morten Schou"],"significance":6,"published":"2021-06-01","source_date":"2021-06-01","image":"","kennis":[],"congress":"","summary_en":"The Empire HF Metabolic trial characterized the metabolic effects of empagliflozin in heart failure, showing favorable shifts in ketone body utilization and energy metabolism that may underlie the cardiac benefit of SGLT2 inhibitors.","created":"2026-07-03T10:29:13Z","updated":"2026-07-03T13:28:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Empire HF Metabolic gerandomiseerde trial naar de metabole effecten van empagliflozine bij hartfalen. Mechanistisch onderzoek.","abstract_original":""}